Coronavirus Notebook: China Focuses On Antivirals As Death Toll Passes SARS
Drugs Put At Center Of Fight
Executive Summary
Chief executives of two antiviral and vaccine developers share with Scrip their development plans and projections as the death toll from the coronavirus outbreak reaches 900 with more cases being confirmed worldwide.
You may also be interested in...
Moderna Marches First Coronavirus Vaccine To US Test
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Ark Bio Of China Bets On Untapped Pediatric Antiviral Market Where Few Have Succeeded
Founded five years ago, Shanghai-based Ark Bio sees big potential in the less crowded pediatric antiviral treatment market. Now the start-up is in Phase II development for its lead asset ziresovir for respiratory syncytial virus (RSV) infection, which was licensed from Roche.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.